RAGE inhibition improved PAH in both animal models by providing beneficial effects on proliferation, apoptosis resistance, and the STAT3/BMPR2/PPARγ axis, thus making this protein a new potential therapeutic target for PAH. This evidence concerns the gene BMPR2 and pulmonary arterial hypertension.